Regeneron falls after reporting EPS below the Street and disclosing patient deaths

Regeneron lost $2.4 billion in market cap Tuesday after reporting 1Q19 EPS well below consensus and disclosing two patient deaths in a Phase I trial evaluating its bispecific mAb targeting CD20 and CD3, REGN1979, in combination with anti-PD-1 mAb Libtayo cemiplimab-rwlc.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) President and CSO George

Read the full 482 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE